Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13275892 | 0.74 | — | — | |
| SCHEMBL1305914 | 0.73 | KDM4E (0.36) | ALDH1A1LMNAPOLB | |
| SCHEMBL4394130 | 0.72 | HPGDS (0.50) | HPGDSALDH1A1NPSR1POLBGAA | |
| SCHEMBL3939344 | 0.71 | NPY5R (0.34) | LMNA | |
| SCHEMBL527479 | 0.69 | DPP4 (0.30) | — | |
| SCHEMBL3524051 | 0.69 | MAPT (0.38) | HPGDSALDH1A1NPSR1LMNA | |
| SCHEMBL17062871 | 0.69 | EPHX2 (0.41) | ALDH1A1LMNA | |
| SCHEMBL3754728 | 0.68 | GFER (0.50) | ALDH1A1NPSR1LMNAPOLBGAA | |
| SCHEMBL1998673 | 0.68 | GPR119 (0.54) | ALDH1A1 | |
| SCHEMBL1306189 | 0.67 | ALDH1A1 (0.35) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2129660-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | Pfizer Products Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HPGDS 984/4885ALDH1A1 148/4885NPSR1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.